New York State Common Retirement Fund Has $116.44 Million Stake in Bristol Myers Squibb Company $BMY

New York State Common Retirement Fund reduced its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 0.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,515,336 shares of the biopharmaceutical company’s stock after selling 17,000 shares during the quarter. New York State Common Retirement Fund owned approximately 0.12% of Bristol Myers Squibb worth $116,435,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at $1,554,154,000. Wellington Management Group LLP boosted its holdings in shares of Bristol Myers Squibb by 297.0% during the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company’s stock worth $1,447,198,000 after buying an additional 17,750,938 shares during the period. GQG Partners LLC grew its stake in Bristol Myers Squibb by 22,647.6% in the 1st quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company’s stock valued at $733,310,000 after buying an additional 11,970,598 shares during the last quarter. Nuveen LLC bought a new position in Bristol Myers Squibb in the 1st quarter valued at about $624,369,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after acquiring an additional 10,195,775 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is owned by company insiders.

Bristol Myers Squibb Stock Down 0.2%

Shares of NYSE BMY opened at $49.18 on Friday. The stock has a market capitalization of $100.11 billion, a P/E ratio of 19.83, a PEG ratio of 2.23 and a beta of 0.33. The stock’s fifty day moving average is $45.59 and its 200 day moving average is $46.63. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same period in the prior year, the company posted $1.80 earnings per share. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.0%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 83.78%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BMY shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a research report on Tuesday, August 5th. Citigroup reduced their target price on shares of Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating for the company in a research report on Monday, November 17th. Finally, Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $54.42.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.